Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
19961.5k citationsCheson Bd, J M Bennett et al.Bloodprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Cheson Bd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheson Bd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheson Bd more than expected).
This network shows the impact of papers produced by Cheson Bd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheson Bd. The network helps show where Cheson Bd may publish in the future.
Co-authorship network of co-authors of Cheson Bd
This figure shows the co-authorship network connecting the top 25 collaborators of Cheson Bd.
A scholar is included among the top collaborators of Cheson Bd based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Cheson Bd. Cheson Bd is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
West, Pamela, et al.. (2001). Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550).. PubMed. 15(9). 1168–5.6 indexed citations
5.
Bd, Cheson, et al.. (2001). Clinical trials referral resource. Current clinical trials of fenretinide.. PubMed. 15(12). 1595–6, 1598, 1600.3 indexed citations
Bd, Cheson, et al.. (1996). Clinical trials referral resource. Clinical trials using bryostatin-1.. PubMed. 10(5). 740–2.12 indexed citations
11.
Ph, Phillips, et al.. (1996). Clinical trials referral resource. Clinical trials using thalidomide.. PubMed. 10(10). 1498, 1501–1498, 1501.2 indexed citations
12.
Bd, Cheson, J M Bennett, Michael R. Grever, et al.. (1996). National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87(12). 4990–4997.1468 indexed citations breakdown →
Bd, Cheson. (1989). Clinical trials referral resource. Adjuvant therapy in breast cancer.. PubMed. 3(11). 55, 60, 65–1, 74.2 indexed citations
18.
Bd, Cheson, et al.. (1987). Current status and future directions of clinical trials in chronic lymphocytic leukemia.. PubMed. 1(8). 31–40, 44.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.